Current Report Filing (8-k)
November 03 2016 - 4:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
October 29, 2016
Date of Report (Date of earliest event reported)
MEDGENICS, INC.
(Exact name of registrant as specified in its charter)
Delaware
|
1-35112
|
98-0217544
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
435 Devon Park Drive, Suite 715
Wayne, Pennsylvania 19087
(Address of principal executive offices,
zip code)
(610) 254-4201
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01.
|
Regulation FD Disclosure.
|
On October 29, 2016, the Company issued
a press release announcing new data confirming the presence of specific genetic mutations in pediatric populations with attention
deficit hyperactivity disorder (ADHD). The press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
The information in this Item 7.01 disclosure,
including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “
Exchange Act
”), or otherwise subject to the liabilities under
that Section. In addition, the information in this Item 7.01 disclosure, including Exhibit 99.1, shall not be incorporated by reference
into the filings of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly
set forth by specific reference in such filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits. The following exhibits are furnished herewith:
Exhibit No.
|
Description
|
|
|
99.1
|
Medgenics, Inc. Press Release dated October 29, 2016 (furnished
pursuant to Item 7.01).
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MEDGENICS, INC.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Brian D. Piper
|
|
|
|
Name: Brian D. Piper
|
|
|
|
Title: Chief Financial Officer
|
|
Date: November 3, 2016
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Sep 2023 to Sep 2024